Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Hyperalgesia Pipeline Review, H1 2019 Report Featuring Abide Therapeutics, Boehringer Ingelheim, Cara Therapeutics, Charleston Laboratories, & Novartis - ResearchAndMarkets.com

May 23, 2019

DUBLIN--(BUSINESS WIRE)--May 23, 2019--

The “Hyperalgesia - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hyperalgesia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hyperalgesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperalgesia (Central Nervous System) pipeline guide also reviews key players involved in therapeutic development for Hyperalgesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Hyperalgesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperalgesia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Hyperalgesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hyperalgesia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hyperalgesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hyperalgesia (Central Nervous System)

Companies Involved in Therapeutics Development

  • Abide Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Cara Therapeutics Inc
  • Charleston Laboratories Inc
  • Novartis AG

Drug Profiles

  • ABX-1431
  • AX-007
  • BAM-822
  • BI-113823
  • CR-701
  • ketoprofen
  • mol-002291
  • Monoclonal Antibody to Inhibit TGF-Beta-1 for Chronic Pancreatitis Pain and Hyperalgesia
  • Small Molecules to Antagonize GPR4 for Arthritis, Hyperalgesia and Oncology
  • ZH-853

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/23v61w

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005443/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Analgesics



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/23/2019 09:31 AM/DISC: 05/23/2019 09:31 AM


All contents © copyright 2019 The Associated Press.All rights reserved.